Status · FDA-approved 2019 — premenopausal HSDD only
Is PT-141 FDA-Approved? Regulatory Status
Approved in 2019 for one specific use, off-label for everything else, and unregulated as a research chemical — the regulatory record set out in full.
The short version
Is PT-141 fda-approved? Yes — but narrowly. The drug, under the name bremelanotide, was approved by the FDA on June 21, 2019, under application number NDA 210557 [7]. The approval covers one use only: acquired, generalized HSDD (hypoactive sexual desire disorder — persistent low desire that causes real distress) in premenopausal women [7].
Every other use is not approved. It is not approved for men, not for postmenopausal women, and not to enhance sexual performance [7][9]. A 2024 program testing it for male erectile dysfunction is still investigational [8]. And material sold as a "PT-141 research chemical" is not the approved drug at all — it sits outside the approval framework with no oversight of what is actually in it [7]. The sections below give the full record.
What was approved, and when
The regulatory facts are precise. The FDA approved bremelanotide injection on June 21, 2019, under NDA 210557 [7]. The approved indication is the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women [7]. The international nonproprietary name is bremelanotide; the research-community name is PT-141 [1].
The approval was supported by the two RECONNECT Phase 3 trials and a 52-week extension, which together met the coprimary endpoints and characterized the safety profile [3][4]. A 2020 analysis of FDA peptide and oligonucleotide approvals records bremelanotide within the strong 2019 cohort of peptide drug approvals [10].
What is off-label or investigational
The boundary of the approval is where most public interest sits, so it deserves to be explicit. Use in men is off-label; the only active male program — bremelanotide co-administered with a PDE-5 inhibitor for erectile dysfunction — is an investigational Phase 2 study announced in 2024, not an approval [8]. Use in postmenopausal women is off-label; the approval is specific to premenopausal women, and a treatment review distinguishes this indication from off-label transdermal testosterone used in postmenopausal women [9].
Use for weight or metabolic effects is not approved either; MC4R also sits in appetite circuits, and the caloric-intake and body-weight effects seen in high-frequency early Phase 1 dosing are a pharmacological consideration, not an indication [2]. Anything framed as "performance" enhancement is outside the approval entirely [7].
The research-chemical distinction
There is a sharp line between the approved drug and the gray-market peptide. Bremelanotide, as the approved pharmaceutical, is manufactured and dispensed under regulatory oversight for its labeled indication [7]. Material sold online as a "PT-141 research chemical" is not that drug: it sits outside the pharmaceutical approval framework, with no regulatory control of identity, purity, or concentration [7].
This distinction is why the label's pharmacokinetics, safety warnings, and efficacy data cannot simply be transferred to research-grade material — they describe the approved product, not whatever a given vial contains [7]. This site documents the published research and the approved label; it dispenses, prescribes, and sells nothing.
Anti-doping and other status
For athletes, the regulatory picture extends to anti-doping. Melanocortin receptor agonists without current therapeutic approval in the relevant context fall under WADA's non-approved-substances framework (the S0 category), so athletes should consult current WADA guidance directly rather than rely on a general summary [7].
In short: PT-141 is FDA-approved as bremelanotide for premenopausal HSDD, off-label or investigational for everything else, unregulated as a research chemical, and subject to anti-doping rules for competitive athletes [7][8]. Every claim on this page maps to a cited source on PT-141 references.